KATHARINE VOGELAAR: Open Payments
NPI 1285144634 · WACO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$367 in 15 payments from 9 companies in 2025. Trend: 2023 $42 · 2024 $301 · 2025 $367
Food & beverage: $367
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 3 | $73 |
| GENZYME CORPORATION | 2 | $51 |
| GlaxoSmithKline, LLC. | 2 | $47 |
| PFIZER INC. | 2 | $44 |
| Ionis Pharmaceuticals, Inc. | 1 | $36 |
| AstraZeneca Pharmaceuticals LP | 2 | $35 |
| CSL Behring | 1 | $34 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $28 |
| Blueprint Medicines Corporation | 1 | $20 |
Products named: AYVAKIT, NUCALA, DAWNZERA, Hizentra, OCTAGAM IMMUNE GLOBULIN (HUMAN), CUVITRU, XOLAIR, Rhapsido.
Industry payments across TX — which companies pay providers there.
